Jiuhong

Chengdu Diao Jiuhong Pharmaceutical Factory is a China-based pharmaceutical company associated with the Diao group and focused on development and manufacturing of natural-product, synthetic, and biologic medicines. Available secondary sources describe the company as established in 1996 in Sichuan and operating as a sizeable drug manufacturer with capabilities spanning natural medicines, gene-engineered products, synthetic drugs, and novel formulations. Public pipeline aggregators indicate that the company has a diversified development portfolio across metabolic, oncology, neurology, infectious, and hematologic areas. Its most visible active clinical program appears to be Zhibitai Capsules, which entered a Phase 2 trial for primary hyperlipidemia in March 2025. The company appears to be a commercial-stage pharmaceutical manufacturer overall, but with limited English-language public disclosure on individual pipeline assets and partnerships.